Advocates from AIDS Healthcare Foundation stepped up efforts to ensure that Gilead Sciences, Inc. be held accountable for promoting off-label use of Truvada for use as pre-exposure prophylaxis (PrEP) to prevent HIV infection.
On Thursday, January 14 the New York Times building in Times Square hosted a multimedia presentation on "Dying Words: The AIDS Reporting of Jeff Schmalz and How It Transformed the New York Times."
Homelessness and HIV/AIDS are two of the biggest issues facing the LGBT community. When the two exist in tandem, the challenges that each condition presents become exasperated.
AIDS Healthcare Foundation (AHF) denounced the $13 billion fundraising goal recently announced by the Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) for the Fifth Replenishment round spanning 2017-2019 as lacking in ambition and low in expect
Access to harm reduction programs such as syringe exchange is lowest in rural and suburban areas, where rates of addiction to heroin and other opioids are on the rise, according to a study led by researchers at the Icahn School of Medicine at Mount Sinai
Fewer than 1 in 4 high school students who've had sex have ever been tested for HIV. That's according to a government study that found the rate didn't budge over eight years, despite recommendations for routine tests.
Through the generous support of the Ford Foundation, AIDS United granted $1.4 million to 21 organizations across Alabama, Florida, Georgia, Louisiana, Mississippi, North Carolina, South Carolina, Tennessee and Texas.
ViiV Healthcare, through its Positive Action for Children Fund, funds 34 new community-based organizations to help eliminate mother to child transmission of HIV across Sub-Saharan Africa.
Adding a vaccine to the comprehensive HIV/AIDS response is essential to conclusively ending the epidemic, according to modeling research published today.
The FDA has approved a new one-pill-a-day HIV treatment regimen called Genvoya, made by Gilead Sciences.